Welcome to our dedicated page for Lyell Immunopharma SEC filings (Ticker: LYEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lyell Immunopharma filings document the regulatory record of a Nasdaq-listed clinical biotechnology company developing next-generation CAR T-cell therapies. Its 8-K reports furnish operating results and business updates for ronde-cel in large B-cell lymphoma and LYL273 in metastatic colorectal cancer and other GCC-expressing cancers, along with cash, financing and clinical-program disclosures.
The company’s filings also cover material agreements, including licensing rights for LYL273, and governance matters such as annual-meeting proposals, director elections, auditor ratification, executive compensation votes, officer appointments and compensatory arrangements. Securities disclosures identify Lyell’s common stock listed on the Nasdaq Global Select Market.
Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc., transferred 44,000 shares of common stock to Wuxiong, Inc. as broker commission tied to a first Development Milestone under a license agreement. The transfer involved no cash consideration and is classified as an “other” disposition. After this transaction, the reporting holder beneficially owns 2,774,980 shares of Lyell common stock.
Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, transferred 38,500 shares of common stock on July 27, 2026 to LifeSci Advisors, LLC as broker commission related to the first Development Milestone payment under a November 6, 2025 license agreement. This non-cash disposition, reported under transaction code J, reduced its beneficial holdings to 2,818,980 shares of Lyell common stock.
Innovative Cellular Therapeutics Holdings Ltd, a ten percent owner of Lyell Immunopharma, Inc., reported a sale of 10 shares of common stock on July 17, 2026 at $13.70 per share. The filer indicated the trade was made under a Rule 10b5-1 trading plan. After this transaction, it directly beneficially owns 2,857,480 shares of Lyell common stock.
Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc., reported a sale of 10 shares of Lyell common stock on 2026-07-16 at $13.73 per share. The trade was made pursuant to a Rule 10b5-1 trading plan, leaving the holder with 2,857,490 common shares afterward, down from 2,857,500 immediately before the sale.
Lyell Immunopharma, Inc. is registering up to 1,100,000 shares of common stock for resale by Innovative Cellular Therapeutics Holdings Limited (ICT Holdings) under a shelf registration. Lyell is not offering any shares itself and will not receive proceeds from sales made by the selling stockholder.
The registered shares were issued to ICT Holdings on July 10, 2026 after achievement of milestones under a November 6, 2025 exclusive license with the Innovative Cellular Therapeutics group. That agreement grants Lyell exclusive rights to certain cell therapy product candidates and products worldwide except mainland China, Taiwan, Macau and Hong Kong.
Upfront consideration under the license included $40 million in cash and 1.9 million Lyell shares, with further potential payments of $30 million in clinical milestones, up to $115 million in late-stage regulatory milestones, up to $675 million in commercial sales milestones, up to 1.85 million additional shares, and tiered royalties up to 10% on U.S. net sales. As of July 10, 2026, ICT Holdings beneficially owned 2,857,500 Lyell shares and would own 1,757,500 shares, or 7.2% of 24,504,358 shares outstanding, if all registered shares are sold.
Innovative Cellular Therapeutics Holdings Ltd, a major shareholder of Lyell Immunopharma, Inc., reported an internal share transfer classified as an "other" transaction. On June 29, it transferred 76,000 shares of Common Stock to Wuxiong, Inc. as broker commission related to an upfront payment under a prior license agreement, for no cash consideration.
Following this restructuring-type transfer, the reporting holder now beneficially owns 2,857,500 shares of Lyell common stock, down from 2,933,500 shares immediately before the transaction. The filing reflects a non-market, compensation-related movement of shares rather than an open-market purchase or sale.
Innovative Cellular Therapeutics Holdings Ltd, a 10% owner of Lyell Immunopharma, Inc., transferred 66,500 shares of common stock on June 15, 2026 to LifeSci Advisors, LLC as broker commission tied to an upfront payment under a license agreement. The transfer was made for no cash consideration and reported as an “other” transaction. Following this move, the reporting holder directly beneficially owns 2,933,500 shares of Lyell common stock.
Innovative Cellular Therapeutics Holdings Limited reports it beneficially owns 3,000,000 shares of Lyell Immunopharma common stock, equal to approximately 12.3% of the class. The reporting person states it became entitled to an additional 1,100,000 shares upon achieving a development milestone under a License Agreement on 05/18/2026.
The filing amends a prior Schedule 13G/A and updates the beneficial ownership totals and voting/dispositive powers; the Reporting Person reports sole voting and dispositive power over the 3,000,000 shares.
Innovative Cellular Therapeutics Holdings Ltd has filed an initial ownership report showing it holds 3,000,000 shares of Lyell Immunopharma, Inc. common stock. These shares reflect equity consideration under a License Agreement between the two companies.
The position consists of 1,900,000 shares received as partial upfront consideration under a License Agreement dated November 6, 2025, and 1,100,000 shares tied to a development milestone achieved on May 18, 2026. Beneficial ownership is deemed acquired when the right to receive the milestone shares became fixed, and all shares are held of record by the reporting entity.